This appraisal has been suspended. Empaglifozin is already recommended for people with type 2 diabetes (TA336) and the population for which this additional appraisal would be aimed at (poorly controlled diabetes plus cardiovascular risk) is already included in the population previously appraised. Cardiovascular endpoints are already part of the case for cost effectiveness of empagliflozin as established in TA336, therefore published NICE guidance already covers indication.
 
Status Suspended
Process STA pre-2018
ID number 1037

Project Team

Project lead Jeremy Powell

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
01 February 2018 Suspended, This appraisal has been suspended. Empaglifozin is already recommended for people with type 2 diabetes (TA336) and the population for which this additional appraisal would be aimed at (poorly controlled diabetes plus cardiovascular risk) is already included in the population previously appraised. Cardiovascular endpoints are already part of the case for cost effectiveness of empagliflozin as established in TA336, therefore published NICE guidance already covers indication.
21 April 2017 Referral
21 April 2017 In progress, Topic referred
22 November 2016 - 20 December 2016 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance